title: Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
abstract: We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials. Despite substantial differences in the reporting patterns of bleeding complications, low-dose ASA was associated with the lowest risk, and moderate doses caused a relatively high hemorrhagic event rate, especially with regard to minor, gastrointestinal, and total bleeding, and stroke. These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg.
authors.affiliation: HeartDrug Research Laboratories, Towson, Maryland, USA. Heartdrug@aol.com <Heartdrug@aol.com>
authors.forename: Victor L
authors.initials: VL
authors.lastname: Serebruany
authors.forename: Steven R
authors.initials: SR
authors.lastname: Steinhubl
authors.forename: Peter B
authors.initials: PB
authors.lastname: Berger
authors.forename: Alex I
authors.initials: AI
authors.lastname: Malinin
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Baggish
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin